secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2026-10-26T21:14:47+00:00
Accession:  0000105770-26-000114
Event type: debt
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 2.03, 1.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

West Pharmaceutical replaces 2019 credit facility with new $750M revolver and $200M term loan
--------------------------------------------------------------------------------

- New $750M revolver and $200M term loan under a five-year credit agreement dated Oct 26, 2026; $130M outstanding under the 2019 facility repaid in full and terminated, no early termination penalties.
- Term loan has quarterly amortization starting March 31, 2028 of $1.25M-$2.5M, balance due at maturity; sublimits of $50M for letters of credit and $90M for swing line loans.
- Pricing scales with Net Leverage Ratio: term SOFR margin 1.000%-1.500% on revolver loans, 1.125%-1.750% on term loans; commitment fee 0.125%-0.225% on unused revolver.
- Covenant caps Net Leverage Ratio at 3.50x, stepping to 4.00x during material acquisition periods; borrowings unsecured with no subsidiary guarantors as of closing.
- Proceeds earmarked for working capital, capex, permitted acquisitions, stock repurchases and debt repayment; optional currencies include euros, yen and Singapore dollars.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577026000114/0000105770-26-000114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577026000114/wst-20261026.htm
  HTML page:      https://secwatch.observer/filing/0000105770-26-000114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer